论文部分内容阅读
目的探讨培美曲赛联合顺铂治疗老年晚期非小细胞肺癌(NSCLC)的疗效。方法对35例老年晚期NSCLC患者采用以下治疗方案:培美曲赛500mg/m2第1天,顺铂25mg/m2第1～3天,21d为1个周期。结果本组CR1例,PR9例,SD14例,PD11例,有效率28.6%,临床受益率68.6%。治疗后生活质量增加8例,稳定11例,下降16例,良好者共19例,良好率54.3%;毒副反应主要为轻度的骨髓抑制及胃肠道反应,经对症处理后均得到有效缓解。结论培美曲赛联合顺铂治疗老年晚期NSCLC的疗效确切,毒副反应轻,能有效提高患者的生活质量,值得临床推广应用。
Objective To investigate the efficacy of pemetrexed combined with cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). Methods 35 cases of elderly patients with advanced NSCLC treated with the following programs: Pemetrexed 500mg / m2 on the first day, cisplatin 25mg / m2 on the 1st to 3 days, 21d for a cycle. Results The group of CR1 cases, PR9 cases, SD14 cases, PD11 cases, the effective rate was 28.6%, the clinical benefit rate was 68.6%. After treatment, the quality of life increased in 8 cases, stable in 11 cases, decreased in 16 cases, good in 19 cases, good rate of 54.3%; side effects mainly mild myelosuppression and gastrointestinal reactions, after symptomatic treatment were effective ease. Conclusion Pemetrexed combined with cisplatin in the treatment of elderly patients with advanced NSCLC has definite curative effect, light toxicity, and can effectively improve the quality of life of patients. It is worthy of clinical application.